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The binding of phosphoenolpyruvate (PEP) to the single allosteric
site on phosphofructokinase (EC 2.7.1.11) from Bacillus stearother-
mophilus (BsPFK) diminishes the ability of the enzyme to bind the
substrate fructose 6-phosphate (Fru-6-P). Comparisons of crystal
structures with either Fru-6-P or phosphoglycolate, an analog of
PEP, bound have shown that Arg-162 interacts with the negatively
charged Fru-6-P. Upon the binding of phosphoglycolate, Arg-162 is
virtually replaced by Glu-161, which introduces a potential cou-
lombic repulsion between enzyme and substrate [Schirmer, T. &
Evans, P. R. (1990) Nature (London) 343, 140–145]. It has previously
been proposed that this structural transition explains the allosteric
inhibition in BsPFK, and this explanation has appeared in textbooks
to illustrate how an allosteric ligand can influence substrate bind-
ing at a distance. Site-directed mutagenesis has been employed to
create three mutants of BsPFK that substitute an alanine residue
for Glu-161, Arg-162, or both. The E161A mutation does not affect
the inhibition of BsPFK by PEP at 25°C, and while the R162A
mutation decreases BsPFK’s affinity for Fru-6-P by approximately
30-fold, R162A diminishes the effectiveness of PEP inhibition by
only 1y3. Combining E161A and R162A produces behavior compa-
rable to R162A alone. These and other data suggest that the
movement of Glu-161 and Arg-162 does not play the central role in
producing the allosteric inhibition by PEP as originally envisioned
in the Schirmer and Evans mechanism.
Phosphofructokinase (EC 2.7.1.11) has been studied exten-sively both structurally and functionally. It is often looked
upon as establishing a paradigm for how regulatory enzymes
come to be imbued with allosteric properties. Phosphoenolpyru-
vate (PEP) allosterically inhibits phosphofructokinase from Ba-
cillus stearothermophilus (BsPFK) by diminishing the affinity the
enzyme displays for its substrate, fructose 6-phosphate (Fru-6-
P). In 1990 Schirmer and Evans (1) proposed a mechanism to
explain this inhibition based on analyses of x-ray crystal struc-
tures of BsPFK. This proposal has become generally accepted as
a quintessential example of how allosteric ligands achieve their
effects as evidenced by its inclusion in popular biochemistry
textbooks (2–4).
A comparison of the structure of the substrate-bound form of
BsPFK (5) to that of BsPFK with an inhibitor analog of PEP,
phosphoglycolate, bound in the allosteric site (6)† reveals a
different conformation in the active site of these two forms. It
was proposed that this conformational change is responsible for
the ability of phosphoglycolate, and by extension PEP,‡ to
diminish the affinity of BsPFK for Fru-6-P. The conformational
change involves a substantial movement of residues Glu-161 and
Arg-162, depending on whether substrate or inhibitor is bound.
When Fru-6-P is bound to the active site of BsPFK, the positively
charged side chain of Arg-162 protrudes into the active site and
favorably interacts with the negatively charged phosphate group
of Fru-6-P. Glu-161 is well removed from the binding site of this
structure. When phosphoglycolate is bound to the allosteric site
of BsPFK with the active site empty, the Arg-162 residue is
positioned away from the active site, and its former location is
occupied by the negatively charged side chain of Glu-161. This
virtual switch in the position of these two oppositely charged
residues introduces a negative charge into the binding site for
Fru-6-P and causes a putative electrostatic repulsion between
the side chain of Glu-161 and an incoming Fru-6-P molecule,
presumably resulting in a decrease in the affinity for Fru-6-P.
We were prompted to reevaluate this mechanism for the follow-
ing reasons: First, the mechanism does not address the issue of
reciprocity that must occur between the binding of a ligand to the
allosteric site and the binding of a substrate in the active site.
Because PEP increases the K1/2 for Fru-6-P approximately 500-fold
at 25°C (7), thermodynamic linkage requires that Fru-6-P inhibit
the binding of PEP to the same extent. It is not clear how the
movement of Glu-161 and Arg-162, both located in the Fru-6-P
binding site, might influence the binding of PEP to the allosteric site
some 20 Å away. Indeed, only a relatively small repositioning of
residues lining the allosteric site is evident, with no obvious
consequences, in the Schirmer and Evans structures (1).
Second, the two crystal structures that form the basis of the
proposal do not by themselves provide enough information. The
actions of a K-type allosteric inhibitor, such as PEP or phospho-
glycolate, are quantitatively described, both in nature and magni-
tude, by a coupling free energy, DGay (7, 8). DGay in turn is the
standard free energy for the following disproportionation equilib-
rium:
Y–E 1 E–Aº Y–E–A 1 E [1]
where E–A and Y–E represent the binary complexes of either
substrate or allosteric ligand bound to the enzyme, respectively
(9–11). E represents native enzyme with no ligands bound and
Y–E–A represents the tertiary complex formed when both
substrate and allosteric ligand are bound. In the present case,
A represents Fru-6-P and Y represents PEP or phosphogly-
colate. One cannot speculate about the poise of the equilib-
rium depicted in Eq. 1 without making explicit or implicit
assumptions about the chemical potential of the unexamined
enzyme forms. E–A and Y–E may be very different, as are the
Fru-6-P-bound and phosphoglycolate-bound forms of BsPFK
according to the x-ray structures, but that difference alone
does not speak directly to the reason why Eq. 1 attains a
particular equilibrium value because both of those enzyme
forms appear on the same side of that equilibrium. No
adequate structural information is currently available pertain-
ing to the E and Y–E–A enzyme forms.
Finally, the proposed mechanism might be interpreted, par-
ticularly by readers of general biochemistry texts, as suggesting
that simple coulombic interactions between Glu-161 or Arg-162
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and Fru-6-P are solely responsible for the different binding
affinities displayed by Fru-6-P in the absence and presence of the
inhibitor. If this were the case, then heat should be released and
absorbed in these two cases, respectively. However, van’t Hoff
analyses for wild-type BsPFK have indicated that the enthalpy
change introduced by PEP actually favors activation, and en-
tropy, not enthalpy, is driving the observed inhibition by PEP at
25°C (7, 8). A simple mechanism dominated by coulombic
interactions does not easily explain this observation.
In 1995 Auzat et al. (12) constructed mutants in BsPFK in
which the active site Glu-161 residue was mutated to either an
alanine or a glutamine residue. While they concluded that
Glu-161 was not a crucial residue for inhibition by PEP, they did
not characterize the extent to which removing residue 161
affected the overall coupling free energy between Fru-6-P and
PEP nor how Glu-161 affects the enthalpic and entropic con-
tributions to the overall coupling free energy.
In an attempt to better characterize the role of both active site
residues Glu-161 and Arg-162 in the ability of PEP to inhibit
BsPFK, we have used site-directed mutagenesis to construct
three mutants of BsPFK in which the active site residues Glu-161
and Arg-162 were first individually, and then simultaneously,
changed to alanine. By exposing these mutants to the same
rigorous thermodynamic characterizations as has previously
been conducted on wild-type BsPFK (7), a more complete
understanding of the extent of participation of these residues in
establishing the coupling free energy between Fru-6-P and PEP
has been obtained.
Materials and Methods
Materials. All chemical reagents used for protein purification,
kinetic assays, and fluorescence measurements were of analytical
grade and purchased from Aldrich, Fisher, or Sigma. The Matrix
Blue A-agarose used for purification of BsPFK was purchased
from Amicon. The coupling enzymes aldolase, triosephosphate
isomerase, and glycerol-3-phosphate dehydrogenase were pur-
chased as ammonium sulfate suspensions from Boehringer
Mannheim. Before use in kinetic assays, the coupling enzymes
were dialyzed extensively against 50 mM 3-(N-morpholino)pro-
panesulfonic acid–KOH (Mops–KOH), pH 7.0y100 mM KCly14
mM MgCl2y0.1 mM EDTA. Creatine kinase, creatine phos-
phate, NADH, and sodium salts of Fru-6-P, ATP, and PEP were
purchased from Sigma. Bicinchoninic acid reagents used in
determining protein concentration were purchased from Pierce.
Site-directed mutagenesis was carried out by using the Promega
Altered Sites In Vitro Mutagenesis System, which included the
pALTER vector and pALTER control vector, T4 DNA poly-
merase, T4 DNA ligase, T4 polynucleotide kinase, and the
oligonucleotides used to confer ampicillin resistance. All other
oligonucleotides were synthesized by using an Applied Biosys-
tems 392 DNAyRNA synthesizer at the Gene Technologies
Laboratory at the Institute of Developmental and Molecular
Biology at Texas A&M University. Deionized distilled water was
used throughout.
Site-Directed Mutagenesis. The plasmid pBR322yBspfk (13),
which contains the gene for BsPFK, was received as a generous
gift from Simon H. Chang (Louisiana State University). The
plasmid was further modified to place the gene for BsPFK in
pALTER behind a lac promoter as described elsewhere (M. L.
Riley-Lovingshimer and G.D.R., unpublished results).
Mutagenesis was performed according to the protocol for the
Promega Altered Sites In Vitro Mutagenesis System, using
single-stranded DNA derived from the pMRyBspfk plasmid
containing the gene for BsPFK in pALTER under the lac
promoter. Three mutagenesis reactions were conducted; one to
construct each of the single mutations E161A and R162A and
one to construct the double mutation E161AyR162A. Selected
ampicillin-resistant mutants were sequenced at the Gene Tech-
nologies Laboratory by the Sanger dideoxynucleotide method,
using an Applied Biosystems sequencer and dye-labeled termi-
nators to verify the sequence of the mutant DNA. The resultant
recombinant expression vectors were transformed into the
DF1020 Escherichia coli host strain by using the calcium chloride
method (14). DF1020 was the generous gift of Robert Kemp
(Chicago Medical School) and is a strain that produces no
wild-type PFK-1 (15, 16).
Protein Purification. Purifications of active site mutants of
BsPFK were performed according to Valdez et al. (17) with the
following minor modifications: DF1020 cells containing the
appropriate mutant plasmid were grown to stationary phase in
Luria–Bertani (LB) broth (Bacto tryptone 10 gyliter, Bacto
yeast extract 5 gyliter, and NaCl 10 gyliter) containing 100
mgyml ampicillin at 37°C. Matrix blue A-agarose (Amicon) was
used rather than Cibacron blue 3GA-agarose type 3000-CL-L
(Sigma). After elution from the column, BsPFK was desalted
by dialysis into storage buffer [50 mM N-(2-hydroxyeth-
yl)piperazine-N9-(3-propanesulfonic acid) (EPPS)y100 mM
KCly14 mM MgCl2y0.1 mM EDTA, pH 8.0], concentrated
with an Amicon concentrator apparatus equipped with a
30,000 molecular weight cut-off filter, and then redialyzed into
storage buffer before being stored at 4°C. Purity of final
enzyme preparation was estimated by using SDSypolyacryl-
amide gel electrophoresis (18) and staining with Coomassie
blue. Protein concentration was determined by using the
bicinchoninic acid protein assay (19).
Enzymatic Activity Assays. Activities of BsPFK were measured by
coupling the reaction catalyzed by BsPFK to the oxidation of
NADH and monitoring the corresponding decrease in the
absorbance at 340 nm. Assays were carried out in 1.0-ml reaction
volumes containing storage buffer, 0.2 mM NADH, 2 mM DTT,
250 mg of aldolase, 50 mg of glycerol-3-phosphate dehydroge-
nase, and 5 mg of triosephosphate isomerase adjusted to pH 8.0
at the appropriate temperature. Creatine kinase and creatine
phosphate were added to regenerate MgATP from MgADP to
alleviate the effects of MgADP on the enzyme. The concentra-
tion of MgATP was kept constant and equal to 3 mM, and the
concentrations of Fru-6-P and the inhibitor PEP were as indi-
cated. Assays were initiated by the addition of 10 ml of BsPFK
that had been appropriately diluted so as not to exceed a change
of 0.1 absorbance unit at 340 nm per min. One unit of activity
is defined as the amount of enzyme needed to produce 1 mmol
of fructose 1,6-bisphosphate per min. Activity measurements
were conducted on Beckman Series 600 spectrophotometers,
using a linear regression calculation to convert change in absor-
bance at 340 nm to enzyme activity.
Steady-State Fluorescence. Steady-state fluorescence intensity was
measured by using an SLM-4800 fluorometer upgraded with ISS
photon-counting and data acquisition electronics. Samples were
excited at 300 nm with a xenon arc lamp and fluorescence was
detected either through a monochromator or through a 2-mm-
thick WG 335-nm cut-on filter. Fluorescence experiments were
carried out in 2-ml reaction volumes containing storage buffer at
pH 8.0 with protein subunit concentration varying from 1 to 5
mM. Fru-6-P or PEP were titrated into the sample and the
emission intensity was monitored as a function of ligand con-
centration. All emission measurements were corrected for blank
contributions and dilution.
Data Analysis. All data analysis was performed on a Power
Macintosh 7100y80AV using Kaleidagraph 3.08 (Synergy Soft-
ware) to fit to the following equations. The concentration of








Fru-6-P that resulted in half-maximal activity, K1/2, was deter-





where v equals the steady-state rate of turnover, Vmax represents
the maximal specific activity, and nH is the Hill coefficient. The
variation in K1/2 as a function of PEP concentration was fit to the
following equation:
K1/2 5 Kia
+ S Kiy+ 1 @Y#Kiy+ 1 Qay[Y]D , [3]
where K1/2 is the concentration of Fru-6-P resulting in half-
maximal activity obtained from Eq. 2; K°ia is the dissociation
constant for the substrate Fru-6-P in the absence of any allosteric
ligand; K°iy is the dissociation constant for the allosteric ligand in
the absence of substrate Fru-6-P; and Qay is the coupling
parameter describing the extent to which the binding of the
allosteric ligand affects the binding of substrate and vice versa as








‘ 5 Qay, [4]
where Kia
‘ and Kiy
‘ represent the dissociation constants for A and
Y, respectively, in the saturating presence of the other ligand. To
be consistent with previously adopted conventions (8, 20, 21), A
represents the substrate Fru-6-P and Y represents the allosteric
inhibitor PEP. By resolving both the terms K°iy and Qay, Eq. 3
allows separate quantification of both effector binding affinity
and the action of the effector once it is bound, respectively.
The coupling parameter, Qay, describes both the nature and
magnitude of the effect that allosteric ligands have on the
binding of substrate. If Qay , 1 the allosteric ligand is an
inhibitor, and if Qay . 1 the allosteric ligand is an activator. If Qay
5 1, then the allosteric ligand has no effect on the binding of
substrate. In the case of the inhibitor PEP, the smaller the value
of Qay, the greater the extent of inhibition of substrate binding.
Qay is related to the standard coupling free energy between
Fru-6-P and PEP, DGay, which in turn is related the standard
coupling enthalpy and entropy, DHay and DSay respectively, by
the following relationships:§
DGay 5 2RTln Qay 5 DHay 2 TDSay. [5]
Note that DGay will be positive for an inhibitor and negative for
an activator.
Results
A comparison of the maximal specific activities, affinities for the
substrate Fru-6-P, and cooperativity of substrate binding of the
§The superscript usually included to denote standard state (°) has been omitted to avoid
confusion with the notation used in the previous equations.
Fig. 1. Fru-6-P saturation profiles for wild type (F) and E161A (E), R162A ( n ),
and E161AyR162A (M) mutants of BsPFK. MgATP concentration was 3 mM.
Other conditions were as described in the text.
Fig. 2. Dependence of the apparent K1/2 for Fru-6-P on increasing concen-
trations of the inhibitor PEP for wild type (F) and E161A (E), R162A ( n ), and
E161AyR162A (h) mutants of BsPFK. K1/2 values were obtained from substrate
saturation profiles such as those shown in Fig. 1. Curves correspond to the best
fit of these data to Eq. 3 described in the text.
Table 1. Steady-state kinetic parameters for wild type and active






Wild type 111 6 1 0.034 6 0.001 1.6 6 0.1
E161A 99 6 1 0.035 6 0.001 1.2 6 0.1
R162A 122 6 2 1.10 6 0.06 1.0 6 0.1
E161A/R162A 108 6 1 1.21 6 0.05 1.1 6 0.1
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E161A, R162A, and E161AyR162A mutants of BsPFK with the
corresponding values previously obtained for wild-type BsPFK is
presented in Fig. 1 and Table 1. Fig. 1 depicts the dependence
of activity as a function of substrate concentration for wild-type
BsPFK and the three active site mutants. Table 1 lists the kinetic
parameters obtained from these data. The only parameter that
differs between wild type and the mutants to a significant degree
is the approximately 30-fold increase in K1/2 for Fru-6-P when
Arg-162 is mutated to Ala. Thus both the R162A and the
E161AyR162A mutants exhibit a high K1/2 for Fru-6-P, whereas
the K1/2 exhibited by E161A is very similar to that for wild type.
To determine whether the residues Glu-161 and Arg-162
influence the binding of PEP or its action in diminishing PFK’s
affinity for Fru-6-P, respectively, one or both of the active site
residues were mutated to an alanine. Fig. 2 shows the depen-
dence of K1/2 for Fru-6-P as a function of PEP concentration
determined from steady-state kinetics for wild-type BsPFK and
for the three active site mutants. It is clear from these data that
PEP inhibits all three mutants, as well as wild type, by increasing
K1/2. Because the rapid-equilibrium assumption is valid for
BsPFK (7), the maximum extent of this increase determines the
value of Qay as indicated by Eq. 4. Qay is virtually identical for
wild type and the E161A mutant. The curves pertaining to the
mutants containing R162A are both displaced upward, consis-
tent with a diminished affinity for Fru-6-P at all concentrations
of PEP. PEP causes a further increase in K1/2 in these mutants,
although not quite to the same extent as wild type. Table 2 lists
the parameters obtained from these analyses. Note that, al-
though the mutations also perturb the binding affinity for PEP
to various degrees as indicated by K°iy in Table 2, the coupling free
energy, DGay, retains at least two-thirds of its wild-type value in
all mutants.
Often ligand binding can also be followed by monitoring the
changes the ligands induce in intrinsic protein fluorescence. For
E. coli PFK, the interactions between substrates and effectors
have been studied extensively in this manner (20–22). However,
in the case of wild-type BsPFK, the single tryptophan is for the
most part unresponsive to conformational changes induced by
ligand binding (23). The only change in the fluorescence prop-
erties of wild-type BsPFK is a 10% decrease in the intensity upon
the binding of the inhibitor PEP to the allosteric site (23). This
change has proven to be sufficient, in wild type and in the
E161AyR162A mutant, to assess the coupling interactions be-
tween Fru-6-P and PEP by monitoring the change in intensity
upon PEP binding as a function of Fru-6-P concentration. As
indicated in Eq. 4, the binding antagonism between Fru-6-P and
PEP should be equally manifest in these experiments. The
resulting values for the apparent dissociation constants for PEP,
Kiy, varied with Fru-6-P concentration as shown in Fig. 3 These
data were fit to an equation analogous to Eq. 3 in which the K°ia
and K°iy terms are switched—i.e., A is the independent variable
and Kiy is the dependent variable. The results are presented in
Table 3. The discrepancy between the values presented in Tables
2 and 3 is likely because of the influence of MgATP, which is
present at a saturating concentration in the kinetics experiments
but absent from the fluorescence experiments. Substantial an-
tagonism between MgATP and Fru-6-P binding in E. coli PFK
has been described previously (24). Despite these differences,
the value of DGay for the mutant is still roughly two-thirds the
value for wild type, in agreement with the behavior observed in
the kinetics experiments.
By using van’t Hoff analyses, the inhibition of wild-type
BsPFK by PEP was previously determined to be entropically
dominated (7, 8). Fig. 4 shows a comparison of van’t Hoff plots
obtained for wild-type and E161A BsPFK. Table 4 lists the
entropic and enthalpic energy contributions for the PEP–Fru-
Fig. 3. Dependence of the apparent dissociation constant for PEP, Kiy, on the
concentration of Fru-6-P for wild type (F) and the E161AyR162A mutant (h)
of BsPFK. Kiy was determined from changes in intrinsic fluorescence after
additions of PEP. Error bars represent 6SE. Curves represent the best fit of the
data to an equation analogous to Eq. 3 as described in the text.
Table 2. Thermodynamic coupling parameters for wild type and all three active site mutants
of BsPFK at 25°C
Enzyme Kia
+ , mM Kiy
+ , mM Qay 3 103
DGay,
kcal/mol
Wild type 0.028 6 0.002 0.040 6 0.004 1.4 6 0.1 3.89 6 0.04
E161A 0.025 6 0.002 0.106 6 0.011 2.5 6 0.7 3.55 6 0.17
R162A 1.16 6 0.06 1.01 6 0.09 23 6 4 2.23 6 0.10
E161A/R162A 0.76 6 0.06 0.166 6 0.019 14 6 1 2.53 6 0.04
Parameters were determined from steady-state kinetics with MgATP 5 3 mM.
Table 3. Thermodynamic coupling parameters for wild type and
the E161A/R162A mutant of BsPFK at 25°C
Enzyme Kia
+ , mM Kiy
+ , mM Qay 3 103
DGay,
kcal/mol
Wild type 0.7 6 0.2 17.9 6 2.7 2.9 6 0.5 13.47 6 0.10
E161A/R162A 14.4 6 4.7 33.9 6 6.2 23 6 4 12.24 6 0.10
Parameters were determined from titrations of intrinsic fluorescence with
[MgATP] 5 0.








6-P coupling obtained from these data according to Eq. 5. As is
true for wild type, the inhibition of E161A BsPFK by PEP is also
entropically dominated, and the value of DHay has a negative sign
as indicated by the positive slope in each case. Note that the
temperature at which the two lines cross is very close to 25°C
(1yK 5 0.00335).
Discussion
It is clear that the roles played by Glu-161 and Arg-162 in the
allosteric inhibition by PEP of BsPFK are greatly overstated by
the mechanism proposed by Schirmer and Evans (1). If this
explanation of PEP inhibition were correct, then removal of the
negatively charged residue Glu-161 should greatly reduce PEP’s
ability to decrease PFK’s affinity for Fru-6-P. However, the
present study shows that removal of this residue causes only a
barely significant decrease in the ability of PEP to inhibit Fru-6-P
binding at 25°C (Fig. 2, Table 2). Also, changing Arg-162 to Ala
causes only a 10-fold decrease in Qay (Fig. 2, Table 2). The same
result was obtained when a fluorescence-based thermodynamic
assay was used to determine the Fru-6-P–PEP coupling in the
double mutant E161AyR162A. (Fig. 3, Table 3). These data
indicate that residues Glu-161 and Arg-162 play relatively minor
roles in the mechanism of PEP inhibition at 25°C, since removal
of both residues still allows PEP to inhibit with a coupling free
energy equal to two-thirds the wild-type value. However, even
this conclusion suggests an over-simplified picture of how these
residues contribute, or fail to contribute, to the structural basis
for the allosteric behavior of BsPFK.
Structural data, such as crystal structure coordinates, are
often useful in establishing reaction mechanisms of enzyme-
catalyzed reactions. However, discrepancies can arise when
structural data are exclusively utilized to deduce thermodynamic
parameters associated with protein–ligand interactions. The
proposed mechanism of inhibition of BsPFK by PEP is one such
example. The essential issue when considering the basis for the
actions of a K-type allosteric ligand is: How does the binding
equilibrium for substrate come to be altered when an allosteric
ligand is bound at a remote site? To understand why a shift
occurs in a binding equilibrium, one must consider the changes
in the chemical potential of both reactants and products of that
equilibrium that are introduced by the prior binding of the
allosteric ligand. Each of the two x-ray structures upon which the
Schirmer and Evans mechanism is based represents, respectively,
only one participant of each of these two equilibria. The Fru-
6-P-bound form of the enzyme represents the product of the
substrate binding reaction in the absence of allosteric ligand, and
the phosphoglycolate-bound form represents the reactant of the
second substrate-binding equilibrium that occurs while phos-
phoglycolate remains bound. Thus the structural attributes of
neither of the two equilibria to be compared are completely
established. This mechanistic proposal therefore must presume
that when Fru-6-P binds with phosphoglycolate bound, Glu-161
remains in place, creating a relatively destabilized product
complex for the second equilibrium, and that Arg-162 is predis-
posed to position itself in the active site of free enzyme without
Fru-6-P being present. No information is known about the
structure of either the free enzyme form or the ternary complex
enzyme form (i.e., with both Fru-6-P and phosphoglycolate
bound) to support either of these assumptions.¶
Our initial skepticism was based in part on the expectation that
a simple coulombic mechanism implies that the basis for the
allosteric effects is primarily enthalpic. This implication seemed
to disagree with our observation of entropy-dominated cou-
plings in BsPFK (7). The data presented in Fig. 4 indicate that
factors other than a pure coulombic repulsion between Glu-161
and the substrate must be responsible for the inhibition. Despite
the fact that the binding free energy for Fru-6-P in the E161A
mutant is virtually identical to wild-type, the change in DH for
binding indeed becomes more negative in the absence of that
negatively charged glutamate, as might be predicted if coulombic
repulsion were involved (Table 4). However, this effect is
completely compensated by an opposing change in DS, so the
effect on phosphoglycolate inhibition, given by DGay, is negligi-
ble at 25°C. An entropy ‘‘problem’’ continues to diminish the
propensity for Fru-6-P to bind after PEP, whether or not Glu-161
is present, and is actually larger when Glu-161 is absent.
The importance of a full thermodynamic reconciliation is
evident when one further considers the influence of the E161A
mutation at other temperatures as revealed in Fig. 4. At low
temperatures, replacing the glutamate does make the enzyme
less susceptible to PEP inhibition because Qay is greater for the
mutant than for wild type. This is a direct consequence of the
more negative value of DHay, which favors activation by PEP and
which therefore acts to decrease the inhibition when low tem-
perature diminishes the contribution that DSay makes to DGay.
However, at high temperatures, replacing the glutamate actually
causes PEP to become a better inhibitor. The adverse coupling
¶A structure has been determined from crystals produced by incubating BsPFK with Fru-6-P
and Pi during crystallization in which the Fru-6-P was removed by subsequent washing.
However, two equivalents of Pi remain bound in these crystals, with one occupying the
same position as the phosphate moiety of Fru-6-P when the latter is bound. This position
is approximately 3 Å from Arg-162 and therefore mimics the electrostatic situation with
Fru-6-P bound.
Fig. 4. van’t Hoff analyses of the coupling between Fru-6-P and PEP for wild
type (F) and the E161A mutant (E) of BsPFK. Wild-type data are from ref. 7.
Table 4. Summary of thermodynamic parameters at 25°C
obtained from van’t Hoff analyses of the coupling parameters








Wild type 3.61 6 0.81 24.31 6 0.81 27.93 6 0.01
E161A 3.58 6 0.76 212.77 6 0.76 216.35 6 0.05
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entropy, which is larger in absolute value in the mutant, becomes
weighted more heavily in its contribution to DGay at high
temperatures. Thus, Glu-161 is involved in the allosteric com-
munication as evidenced by the thermodynamic perturbations
resulting from its removal, but this involvement is quite different
and apparently more indirect than that envisioned by the
Schirmer and Evans mechanism.
Finally, the currently available structural information fails to
address the reciprocity requirement of allosteric behavior. The
data in Fig. 3 demonstrate directly that Fru-6-P binding must also
inhibit PEP binding to an identical extent. Changes in the binding
sites themselves would seem unlikely to provide a sufficient
explanation for allosteric behavior in general because the effect
of each ligand on the other must be equal in nature and
magnitude. There must therefore be a region of mutual influ-
ence to serve as the ‘‘conduit’’ for this information transfer from
one site to another. Although the location or even the nature of
this conduit cannot be predicted a priori, it must extend contin-
uously from one site to another. Moreover, the energetic per-
turbations that occur throughout the conduit will contribute to
the overall energetics, and hence the observed phenomenology,
of the allosteric effect. It is very unlikely that structural changes
localized to only one site can provide a complete explanation for
the mechanism underlying an allosteric effect. In the case of
BsPFK, clearly more investigation will be required before a
convincing mechanism can be proposed.
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